Cingulate Inc
NASDAQ:CING

Watchlist Manager
Cingulate Inc Logo
Cingulate Inc
NASDAQ:CING
Watchlist
Price: 4.63 USD -8.86% Market Closed
Market Cap: 31.3m USD

Relative Value

CING doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CING.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CING Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-23.4
Industry
21.6
Forward
-1.7
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-18.1
Industry
16.9
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-22.2
Industry
22.9
vs History
50
vs Industry
61
Median 3Y
5.1
Median 5Y
8.5
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-12.4
Industry
13.4
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-24.3
Industry
16.7
Forward
-1.6
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-18.3
Industry
16.1
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-18.1
Industry
18.9
vs History
80
vs Industry
66
Median 3Y
14.9
Median 5Y
22.9
Industry
2

Multiples Across Competitors

CING Competitors Multiples
Cingulate Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cingulate Inc
NASDAQ:CING
31.3m USD 0 -1.4 -1.4 -1.4
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.5B CHF 4.4 28.8 12.3 14.3
UK
AstraZeneca PLC
LSE:AZN
220.2B GBP 5.1 31.4 108.9 159.4
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
216.1B CHF 4.8 18.8 11.9 15.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/S Multiple
Revenue Growth P/S to Growth
US
Cingulate Inc
NASDAQ:CING
Average P/S: 71.9
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
16.9
26%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
5.3
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.4
3%
1.5
UK
AstraZeneca PLC
LSE:AZN
5.1
8%
0.6
US
Merck & Co Inc
NYSE:MRK
4.3
4%
1.1
CH
Novartis AG
SIX:NOVN
4.8
5%
1
DK
Novo Nordisk A/S
CSE:NOVO B
5.4
5%
1.1
IE
E
Endo International PLC
LSE:0Y5F
92.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
P/E Multiple
Earnings Growth PEG
US
Cingulate Inc
NASDAQ:CING
Average P/E: 24.8
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
18.8
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cingulate Inc
NASDAQ:CING
Average EV/EBITDA: 440
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
11.9
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cingulate Inc
NASDAQ:CING
Average EV/EBIT: 1 883.6
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.3
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5